Switch theme
Sign up to access all valuation multiples
Biogened SA is a Polish cosmetic company. The company defined its key areas of activity, concentrated its efforts on the development of neurological and psychiatric products. It also develops, produces and distributes ingredients, safe and effective dermo cosmetics under the Dermedic brand.
2007
154
Last FY Revenue $29.4M
Last FY EBITDA $3.5M
$24.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Biogened achieved revenue of $29.4M and an EBITDA of $3.5M.
Biogened expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biogened valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $29.4M | XXX | XXX | XXX |
| Gross Profit | XXX | $20.3M | XXX | XXX | XXX |
| Gross Margin | XXX | 69% | XXX | XXX | XXX |
| EBITDA | XXX | $3.5M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 12% | XXX | XXX | XXX |
| EBIT | XXX | $2.4M | XXX | XXX | XXX |
| EBIT Margin | XXX | 8% | XXX | XXX | XXX |
| Net Profit | XXX | $1.2M | XXX | XXX | XXX |
| Net Margin | XXX | 4% | XXX | XXX | XXX |
| Net Debt | XXX | $4.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Biogened's stock price is PLN 31 (or $8).
Biogened has current market cap of PLN 75.2M (or $19.9M), and EV of PLN 91.0M (or $24.1M).
See Biogened trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $24.1M | $19.9M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Biogened has market cap of $19.9M and EV of $24.1M.
Biogened's trades at 0.8x EV/Revenue multiple, and 6.8x EV/EBITDA.
Equity research analysts estimate Biogened's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biogened's P/E ratio is not available.
See valuation multiples for Biogened and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $19.9M | XXX | $19.9M | XXX | XXX | XXX |
| EV (current) | $24.1M | XXX | $24.1M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 6.8x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 10.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 16.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -60.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBiogened's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Biogened's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biogened's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Biogened and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 49% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 61% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biogened acquired XXX companies to date.
Last acquisition by Biogened was XXXXXXXX, XXXXX XXXXX XXXXXX . Biogened acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Biogened founded? | Biogened was founded in 2007. |
| Where is Biogened headquartered? | Biogened is headquartered in Poland. |
| How many employees does Biogened have? | As of today, Biogened has 154 employees. |
| Is Biogened publicy listed? | Yes, Biogened is a public company listed on WAR. |
| What is the stock symbol of Biogened? | Biogened trades under BGD ticker. |
| When did Biogened go public? | Biogened went public in 2011. |
| Who are competitors of Biogened? | Similar companies to Biogened include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Biogened? | Biogened's current market cap is $19.9M |
| Is Biogened profitable? | Yes, Biogened is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
